Class / Patent application number | Description | Number of patent applications / Date published |
546115000 | Ring oxygen in the bicyclo ring system | 8 |
20100249417 | NOVEL NAPHTHYRIDINE DERIVATIVE MONOHYDRATE AND METHOD FOR PRODUCING THE SAME - Disclosed is 1-(2-(4-((2,3-dihydro(1,4)dioxino(2,3-c)pyridin-7-ylmethyl)amino)piperidin-1-yl)ethyl)-7-fluoro-1,5-naphthyridin-2(1H)-one monohydrate, which has strong antibacterial activity. The compound is highly safe and useful as an original drug for pharmaceutical preparations. Also disclosed is a method which is useful for producing 1-(2-(4-((2,3-dihydro(1,4)dioxino(2,3-c)pyridin-7-ylmethyl)amino)piperidin-1-yl)ethyl)-7-fluoro-1,5-naphthyridin-2(1H)-one monohydrate. | 09-30-2010 |
20130116436 | PROCESS FOR PREPARING PYRANO - [2,3-C]PYRIDINE DERIVITAVES - The present invention relates to a process comprising the step of dehydrating a compound of Formula (I): | 05-09-2013 |
546116000 | Acyclic chalcogen bonded directly to ring carbon of the bicyclo ring system | 6 |
20090062547 | CYCLIC-FUSED BETA-LACTONES AND THEIR SYNTHESIS - The present invention provides a concise synthetic method for generating lactam-fused beta-lactones that feature, in some embodiments, a tertiary fused carbinol, quaternary carbons, and a reactive beta-lactone moiety available for further reactions. The present invention further provides compounds synthesized by this method as well as methods of using these compounds as inhibitors of the proteasome and fatty acid synthase. | 03-05-2009 |
20110092706 | Process for the manufacture of enantiomerically pure aryloctanoic acids as aliskiren - The present invention relates to a novel manufacturing process and novel intermediates useful in the synthesis of pharmaceutically active compounds, especially rennin inhibitors such as Aliskiren. The invention describes a preparation of enantiomerically pure 8-aryloctanoic acids of general formula I from readily available key intermediate, a novel bicyclic compound of formula IV. | 04-21-2011 |
20110224439 | Process for Manufacturing 5-Chloromethyl-2,3-Pyridine Dicarboxylic Acid Anhydrides - A process for manufacturing 5-chloromethyl-2,3-pyridine dicarboxylic acid anhydrides (I) | 09-15-2011 |
20110245505 | Process for Manufacturing 5-Formyl-Pyridine-2,3-Dicarboxylic Acid Esters - A process for manufacturing a 5-formyl-pyridine-2,3-dicarboxylic acid ester (I) wherein Z is hydrogen or halogen; Z | 10-06-2011 |
20110251396 | Enantiomeric compositions of cicletanine, alone and in combination with other agents, for the treatment of disease - Preferred embodiments of the present invention are related to novel therapeutic drugs and drug combinations, and associated methods, for treating and/or preventing complications in patients with diabetes, metabolic syndrome, and/or hypertension. More particularly, aspects of the present invention are related to the use of cicletanine as a monotherapy or in combination with other agents for treatment of disease. Cicletanine, as either a monotherapy or in combination with other drugs, may have the form of a non-racemic mixture of the negative (−) and positive (+) enantiomers of cicletanine, or as either the (−) or (+) enantiomer alone. | 10-13-2011 |
20140206873 | Process for Manufacturing 5-Chloromethyl-2,3-Pyridine Dicarboxylic Acid Anhydrides - A process for manufacturing 5-chloromethyl-2,3-pyridine dicarboxylic acid anhydrides (I) | 07-24-2014 |